Creo Medical Group plc

("Creo" the "Company" or the "Group")

Award of Shares under Share Incentive Plan, Director Dealings, Issue of Equity and TVR

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, implemented an HMRC approved Share Incentive Plan ("SIP") during 2020 which is available to all of the Company's UK based employees, including Directors.

Under the SIP, shares are acquired in four ways:

·    Partnership Shares where an employee can spend up to a £1,800 or 10% of their pre-tax income, whichever is the lower;

·    Matching Shares, where Creo can give up to two free Matching Shares for each Partnership Share bought.  The plan requires employees to remain in employment for three years to benefit from the Matching Shares;

·    Free Shares, where Creo can give up to £3,600 of free shares in any tax year; and

·    Dividend Shares where additional shares can be bought with any dividends paid.

The Company has been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"), the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 227,084 ordinary shares in the Company ("Ordinary Shares"), at a price of £0.3275 per Ordinary Share on 16 July 2024 to meet its obligations under the SIP.  Under the terms of the SIP, the Company is required to issue to the SIP, two Ordinary Shares in the Company for each Partnership Share purchased (being 454,168 Ordinary Shares in total).  Fiduchi holds 150,740 unallocated shares within the SIP (being shares previously allocated to employees who ceased employment before the shares had vested) which can be utilised to part satisfy the Company's obligation. Accordingly, 303,428 new Ordinary Shares are required to be issued by the Company to be held by Fiduchi as trustee of the SIP.

Craig Gulliford, Richard Rees and Christopher Hancock, executive directors of the Company (the "Participating Directors") have received Partnership Shares at a price of £0.3275 per share and Matching Shares at a price of £0.001 per share in accordance with terms of the SIP (the "Transaction"). Following this the Participating Directors' shareholdings in the Company are as set out in the table below:

[1] This figure includes 1,000,000 shares held by Mr Gulliford’s wife.

Accordingly, the Company announces that it has made an application for 303,428 new Ordinary Shares to be admitted to trading on AIM.  It is expected that admission will take place on 6 August 2024.  Following the allotment and issue, the Company's issued share capital consists of 361,779,870 Ordinary Shares. The Company does not hold any shares in Treasury. As such the total number of shares in issue with voting rights is 361,779,870.

Total Voting Rights (TVR)

The above figure of 361,779,870 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail in relation to the award of the SIP Shares to the Participating Directors.

Enquiries:

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com